How Will Genetic Technologies Navigate Its DOCA and Cash Crunch?

Voluntary Administration and Recapitalisation Efforts

Genetic Technologies Limited (ASX:GTG) continues to navigate a challenging restructuring phase, remaining under voluntary administration throughout the March 2025 quarter. The company appointed FTI Consulting’s Ross Blakeley and Paul Harlond as joint voluntary administrators in November 2024, a move aimed at stabilising the business and exploring recapitalisation options.

Following creditor approval at a February meeting, the company entered into a Deed of Company Arrangement (DOCA) in March 2025. This legal framework is designed to facilitate the company’s financial restructuring and enable a potential return to operational viability. The administrators have since been working to implement the DOCA and progress the recapitalisation process.

Sale of geneType Business

In a significant step to shore up finances, Genetic Technologies completed the sale of its geneType business and associated assets to Rhythm Biosciences Limited in December 2024 for $625,000 plus GST. This transaction included intellectual property rights, licences, research assets, and customer contracts, as well as the transfer of certain Australian employees and their entitlements.

During the March quarter, the company received $510,000 in proceeds from this sale, which was reflected as investing cash inflows. The divestment marks a strategic exit from the geneType segment, potentially allowing the company to focus on other areas or restructure its core operations.

Financial and Operational Status

Despite these efforts, Genetic Technologies’ financial position remains strained. The company reported a net cash outflow from operating activities of $1.241 million for the quarter, with cash receipts from customers falling sharply to $485,000, down $1.135 million from the previous quarter. This decline reflects the fact that the business was not actively trading during the period, with cash inflows largely residual and related to the administration process.

At quarter end, the company held just $270,000 in cash and cash equivalents, a significant reduction from $1.013 million at the start of the quarter. No payments were made to related parties during this period, indicating tight financial controls under the administration.

Looking Ahead

The successful implementation of the DOCA and recapitalisation remains critical for Genetic Technologies’ future. While the sale of the geneType business has provided some liquidity, the company’s limited cash reserves and ongoing net operating outflows underscore the urgency of securing additional funding or restructuring support. Investors will be watching closely for updates on the recapitalisation progress and any plans to resume trading activities.